(Re)Ordered: DoD Revises and Reorders ASBCA Rules
Client Alert | less than 1 min read | 07.23.14
On July 21, DoD published a final rule to update the Rules of the Armed Services Board of Contract Appeals, "revis[ing] and reorder[ing] the Board's Rules for clarity and consistency and account[ing] for changes in technology." Attached is a redline document reflecting the changes to the Board's rules, which, notably, formalize prior guidance on issues such as summary judgment briefing and filing by electronic mail and add two addendums: (1) Equal Access to Justice Act Procedures, and (2) Alternative Methods of Dispute Resolution.
Contacts
Insights
Client Alert | 7 min read | 09.14.26
AI in Life Sciences: Ten Legal Considerations and Risks of AI Use in Drug Discovery and Development
Over the past several years, the biopharmaceutical industry has embraced artificial intelligence and machine learning (AI/ML) in near lockstep with the pace of AI/ML innovations. Today, industry leaders are using AI/ML to, among other things: discover and assess biological pathways, target chemical structures and sequences; design proteins; model pre-clinical and clinical trials; recruit and screen potential patient populations; evaluate clinical trial results and biomarker data; prepare regulatory filings; and manage supply chains. Deployment of new AI/ML models promises extraordinary advances in pharmaceutical development. However, as with any technological and scientific advances, the use of AI/ML also poses substantial legal risks that life sciences companies need to consider and proactively manage.
Client Alert | 6 min read | 09.14.26
Mental Health Parity Bulletin Restates Best Practices for Evaluating Compliance
Client Alert | 6 min read | 09.11.26
It’s LIVE: The Cyber Resilience Act Reporting Is Mandatory as of Today - 11 September 2026
Client Alert | 10 min read | 09.11.26
Mining, Indigenous Consultation Rights, and Investment Treaty Protection
